By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


Company News
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Study Commences For Patients With Two Relapsed/Refractory Blood Cancers 5/28/2015 7:26:28 AM
AbbVie (ABBV) Completes Acquisition Of Pharmacyclics (PCYC) 5/26/2015 6:42:12 AM
AbbVie (ABBV) Announces Expiration Of Hart-Scott-Rodino Waiting Period AbbVie's Acquisition Of Pharmacyclics (PCYC) 5/22/2015 6:15:18 AM
Pharmacyclics (PCYC) Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia 5/22/2015 6:11:55 AM
AbbVie (ABBV) Announces Offer Consideration For Acquisition Of Pharmacyclics (PCYC) 5/21/2015 8:33:38 AM
AbbVie (ABBV) Extends Exchange Offer To Acquire Pharmacyclics (PCYC) 5/18/2015 7:21:50 AM
Pharmacyclics (PCYC) Release: New ibrutinib (IMBRUVICA) Data To Be Showcased At ASCO Annual Meeting 5/14/2015 11:05:21 AM
AbbVie (ABBV) Extends Exchange Offer To Acquire Pharmacyclics (PCYC) 5/4/2015 9:25:41 AM
Pharmacyclics (PCYC) Reports First Quarter 2015 Financial Results And Provides Business Updates 5/1/2015 8:35:13 AM
Pharmacyclics (PCYC) Release: Ibrutinib (IMBRUVICA) Improves OutcomesFor Pancreatic Ductal Adenocarcinoma In Mouse Models 4/20/2015 12:06:33 PM